Nakamura, Kouki
Kamei, Kazumasa
Austin, Jenny
Marwaha, Simran
Piercy, James
Anderson, Peter
Sakaki-Yumoto, Masayo http://orcid.org/0009-0001-8781-452X
Ohyama, Manabu
Article History
Received: 15 September 2023
Accepted: 2 November 2023
First Online: 11 December 2023
Declarations
:
: Kouki Nakamura, Kazumasa Kamei and Masayo Sakaki-Yumoto are employed by Pfizer Japan Inc. and hold stock in Pfizer Inc. Pfizer Inc. is a global manufacturer/distributor of ritlecitinib, a JAK3/TEC family kinase inhibitor which is approved for alopecia areata by representative medical agencies, including the U.S. Food and Drug Administration, European Medicines Agency and Pharmaceuticals and Medical Devices Agency (Japan). Manabu Ohyama receives lecture fees from Eli Lilly Japan and Pfizer Inc.; advisory fees from Eli Lilly Japan, Pfizer Inc., Maruho Co., Bristol Myers Squibb Japan., Taisho Pharmaceutical Co., AbbVie GK. and ROHTO Pharmaceutical Co.; and research grants not directory related with this study from Maruho Co., Shiseido Co, Advantest Corp. and Sun Pharma Japan Ltd. Jenny Austin, Simran Marwaha, James Piercy and Peter Anderson are employed by Adelphi Real World.
: Patients and physicians provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. Data were collected anonymously; all data were aggregated and de-identified before receipt. The DSP was performed in accordance with relevant legislation, including the US Health Insurance Portability and Accountability Act (HIPAA) 1996 [CitationRef removed]. It was submitted to the Western Institutional Review Board for methodological review in 2019 (study protocol no.: AG8446) and was granted an exemption.